Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi

Stephen B. Gordon,* Stonard Kanyanda,* Amanda L. Walsh,* Kirsty Goddard,* Mas Chaponda,† Victoria Atkinson,† Wakisa Mulwafu,† Elizabeth M. Molyneux,† Ed E. Zijlstra,† Malcolm E. Molyneux,* and Steve M. Graham*

Streptococcus pneumoniae infections can be prevented by using new conjugate vaccines, but these vaccines have limited serogroup coverage. We report the first serogrouping data from carried and invasive isolates obtained from children and adults in Malawi. The 7-valent vaccine would cover 41% of invasive isolates from children and 25% from adults. A 9-valent vaccine, including types 1 and 5, would cover 66% of invasive isolates from children and 55% from adults.

S. pneumoniae is the leading cause of bacterial meningitis in both children and adults in Malawi, as well as an important cause of pneumonia, bacteremia, and death for all ages (1,2). The incidence of S. pneumoniae was reduced in the United States and Europe after the licensing of a 7-valent pneumococcal conjugate vaccine (3), and the Global Alliance for Vaccines and Immunization (available from: URL: http://www.vaccinealliance.org) has plans to expand the use of the vaccine to sub-Saharan Africa (4). However, few data from the central African region exist on which to base a pneumococcal conjugate vaccination program.

Methods

Collection of Pneumococcal Isolates
Queen Elizabeth Central Hospital, the main referral hospital for southern Malawi, admits approximately 12,000 children and 10,000 adults per year. From 1996 to 1998, blood cultures and cerebrospinal fluid (CSF) samples were taken from patients admitted to emergency in whom they were indicated. Guidelines suggest that blood cultures should be taken from all febrile patients and lumbar puncture performed if two of three clinical findings (headache, fever, and altered consciousness) indicate meningitis. S. pneumoniae were identified from these samples by using colony morphology on blood agar, optochin sensitivity, and Gram stain. All S. pneumoniae isolates collected from these samples were stored in bead and broth bacterial cryopreservers (Prolab Diagnostics, Ontario, Canada) at −80°C for serogrouping at a later date.

Carriage Study
From March to July 1998, we collected samples from 250 children and 500 adults by using a single posterior nasal swab, with a sterile cotton swab dipped in saline. The swab was then directly rolled on to a sheep blood agar plate and incubated overnight. Colony subcultures with typical morphologic findings were placed on a second blood agar plate with an optochin disc and cultured at 35°C and 5% CO₂. After 18–24 hours, colonies selected on the basis of typical colony morphologic findings and Optochin sensitivity were stored at −80°C.

Serogrouping
Stored isolates were recultured for typing by using both sheep blood agar plates and enrichment broth (brain heart infusion and Vitox [Oxoid, Basingstoke, U.K.]). Pneumococcal serogrouping was performed with the Quellung reaction with a standard technique (5) and a diagnostic kit from Statens Serum Institut (SSI), Copenhagen, Denmark. This diagnostic kit uses a matrix to group pneumococci covered by the 23-valent pneumococcal vaccine but does not allow typing of pneumococci to the 90 described capsular types. All serogrouping was performed by two investigators (S.B.G was trained at the World Health Organization [WHO] Pneumococcal Reference Laboratory at SSI, Copenhagen; he trained S.K. who sent a set of serogrouped isolates and isolates that could not be typed by kit to SSI for confirmation of accurate technique).

Results
A total of 628 invasive pneumococcal isolates were collected from the emergency pediatric and medical service. These isolates consisted of 114 pediatric blood cultures, 206 pediatric CSF samples, 208 adult blood cultures, and 100 adult CSF samples. In the carriage study, 105 isolates were collected from 250 children (42% carriage) and 54 isolates were collected from 500 adults (10.8% carriage). Because of a storage accident, some isolates (predominantly pediatric CSF samples) thawed and were not recovered. The total isolates available for serogrouping was 428 (Figure).
The potential coverage of invasive pneumococcal isolates offered by the available 7-valent vaccine was poor in Malawi. Previous estimates have suggested that conjugate vaccine coverage in this region would be 70% to 88% (9). We tested a large number of isolates; although some were lost before serogrouping could be performed, the lost isolates probably did not alter the serogroup distribution in our study. In 1980 before the 23-valent polysaccharide vaccine was formulated, serogroups 1 and 5 were considered essential in vaccines for use in Africa (6); a 9-valent vaccine, including serogroups 1 and 5, is already under trial in the Gambia and South Africa (4). Our study indicates that the inclusion of types 1 and 5 will make a substantial difference to the efficacy of the vaccine in Malawi. Alternatively, protein vaccines may have high efficacy against a still wider range of pneumococci.

Antibiotic use is very low in Malawi compared with other parts of the world, and *Pneumocystis carinii* pneumonia prophylaxis is almost unknown because of the lack of healthcare provision. Very low rates of pneumococcal resistance to penicillin (14%), chloramphenicol (24%), and erythromycin (1%) exist in Malawi (10). However, resistance to co-trimoxazole is high (94%) because of the use of sulphamethaxazole-pryrimethamine as first-line anti-malarial drug therapies (11). We were not able to compare the incidence of different serotypes between resistant and nonresistant strains because of the small numbers of penicillin-, chloramphenicol-, or erythromycin-resistant isolates and the small number of cotrimoxazole-sensitive isolates.

HIV infection is a particular problem in Malawi, both in adults and children. An estimated 18% of pediatric hospital patients, 72% of adult hospital patients, and 95% of adults with invasive pneumococcal disease are seropositive for HIV in Blantyre, Malawi (12). Conjugate vaccine is safe and immunogenic in HIV-infected persons (13), and conjugate vaccine was shown to be effective in HIV-infected children, albeit at lower levels than in non–HIV-infected children (14). The vaccine coverage of pneumococcal types, vaccine percentage efficacy, and stage of HIV disease in vaccine recipients are critical determinants of whether this strategy will be of value in adults. However, exposure to children carrying pneumococci is a known risk factor for invasive pneumococcal disease in adults (4). Therefore, reduced carriage of disease-causing pneumococcal strains in children could reduce the adult incidence of invasive pneumococcal disease in this population. Pneumococcal serogroups will continue to be monitored in disease-causing isolates so that vaccine can be implemented in a timely manner.

**Acknowledgments**

We thank the volunteers, staff, and patients of the Queen Elizabeth Central Hospital, Blantyre, Malawi, for their cooperation with this study; Helle Bossen Konradsen and the staff of the World Health Organization Pneumococcal Reference Laboratory.
Statens Serum Institut, Copenhagen, Denmark, for training in serogrouping and confirmation of results; and the laboratory staff of the Wellcome Trust Research Laboratories, Blantyre, Malawi, for technical assistance.

This work forms part of the Malawi-Liverpool-Wellcome Trust Programme of Research in Clinical Tropical Medicine. Financial support was provided by from the Wellcome Trust of Great Britain.

Dr. Gordon holds a Wellcome Trust Career Development Fellowship. His main research interest is susceptibility to infection in HIV-infected adults and the role of pulmonary defense mechanisms.

References

1. Molyneux EM, Walsh AL, Forsyth H, Tembo M, Mwenechanya J, Kayira K, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002;360:211–8.
2. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Mbvwinji M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000;31:53–7.
3. Black S, Shinefield H, Fireman B. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine for children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187–95.
4. Whitney CG. The potential of pneumococcal conjugate vaccines for children. Pediatr Infect Dis J 2002;21:961–70.
5. Sorensen UBS. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 1993;31:2097–100.
6. Greenwood BM, Hassan-King M, Onyemelukwe G, Macfarlane JT, Tubbs HR, Tugwell PJ, et al. Pneumococcal serotypes in West Africa. Lancet 1980;1:560.
7. Crewe-Brown HH, Karstaedt AS, Saunders GL, Khoosal M, Jones N, Wasas A, et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997;25:1165–72.
8. Scott JA, Hall AJ, Hanington A, Edwards R, Mwarumba S, Lowe B, et al. Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya. Clin Infect Dis 1998;27:1442–50.
9. Hausdorff WP, Bryant J, Paradiso PR, Sibler GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100–21.
10. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbvwinji M, Molyneux ME, et al. Bacteraemia and mortality among adult medical admissions in Malawi—predominance of non-typhi salmonellae and Streptococcus pneumoniae. J Infect 2001;42:44–9.
11. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN, Barat LM, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis 2000;181:1501–5.
12. Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, et al. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS 2002;16:1409–17.
13. Feikin DR, Eli CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20:545–53.
14. Madhi SA. Vaccinating against Streptococcus pneumoniae—the new generation vaccine. South African Respiratory Journal 2002;8:35–42.

Address for correspondence: Stephen Gordon, Wellcome Trust Research Laboratories, P.O. Box 30096, Blantyre, Malawi; fax: +265 1 675744; email: sgordon@mlw.medcol.mw
Author/s: Gordon, SB; Kanyanda, S; Walsh, AL; Goddard, K; Chaponda, M; Atkinson, V; Mulwafu, W; Molyneux, EM; Zijlstra, EE; Molyneux, ME; Graham, SM

Title: Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi

Date: 2003-06-01

Citation: Gordon, SB; Kanyanda, S; Walsh, AL; Goddard, K; Chaponda, M; Atkinson, V; Mulwafu, W; Molyneux, EM; Zijlstra, EE; Molyneux, ME; Graham, SM, Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi, EMERGING INFECTIOUS DISEASES, 2003, 9 (6), pp. 747 - 749

Persistent Link: http://hdl.handle.net/11343/234058

File Description: Published version